Conditions: Sleep Disorders Obstructive Sleep Apnea Major Depressive Disorder Dysthymic Disorder
Keywords: Obstructive Sleep Apnea/Hypopnea Syndrome Excessive Sleepiness
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 249
Healthy volunteers: no

Brief summary:
The primary objective of the study is to evaluate whether armodafinil at a target dosage of 200 mg/day is more effective than placebo treatment in improving excessive sleepiness in patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) who have comorbid major depressive disorder or dysthymic disorder.

Detailed description:

Arms:
arm 1: armodafinil 200 mg/day arm 2: Placebo

Interventions: intervention 1: armodafinil intervention 2: placebo
Intervention descriptions: intervention 1: 200 mg/day intervention 2: placebo

Protocol document: